From: Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration
Classification of bleeding
Total (n = 701)
150 mg and 110 mg twice daily (n = 675)
75 mg twice daily (n = 26)
P-value
Major bleeding
11 (1.6%)
0 (0.0%)
1.000
Any bleeding
57 (8.1%)
54 (8.0%)
3 (11.5%)
0.461